Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4221 | Video based aerobic exercise Wiki | 0.71 |
Navigate: Correlations HPO
There are 2 clinical trials
Pneumonia caused by coronavirus infection COVID-19 is characterized by a combination of several dangerous factors that consistently worsen the patient's condition: viral lung damage early in the disease; a sharp increase in inflammation on the background of an unbalanced immune response ("cytokine storm"); joining a bacterial infection. The condition of patients deteriorates significantly mostly at cytokine storm development. The damaging of a large volume of lung tissue leads to develops of respiratory failure, respiratory distress syndrome, or shock. Ventilatory support becomes ineffective and patients die. There are reports of the effectiveness of Human Normal Immunoglobulin for Intravenous Administration (IVIG) high doses when used as part of complex therapy in patients with pneumonia caused by coronavirus COVID-19. In particular, IVIG has a positive effect on survival rates, overall disease course, duration of stay in the intensive care unit, and ventilatory support duration. The probable mechanism of action of high-dose IVIG therapy is considered to be a regulatory effect on the immune system. Similar is the known and confirmed effectiveness of IVIG for autoimmune diseases (Kavasaky disease, Guillain Barre syndrome, Chronic inflammatory demyelinating polyradiculoneuropathy, Multifocal motor neuropathy). This trial to assesses the Efficacy of IVIG (medication trade name - Bioven, manufactured by Biopharma Plasma LLC) in the High Immunomodulatory Dose in Complex Treatment of Severe Pneumonia Caused by COVID-19 / SARS-CoV-2
Description: Number of days post-onset of severe pneumonia to the moment of normalization at least two from following primary outcomes: O2 saturation with self-breathing, respiratory movements rate with self-breathing, body temperature without antipyretics use, lymphocyte count (targeted levels set in the description each of these primary outcomes)
Measure: Period duration (in days) to clinical improvement Time: From date post-onset of severe pneumonia to date of patient discharge or date of death, whichever came first, assessed up to 28 daysDescription: The target level of SPO2 percentage - 95% and above with self-breathing, is used as one of the clinical improvement criteria
Measure: O2 saturation (SPO2 percentage), with self-breathing Time: From date post-onset of severe pneumonia to date of patient discharge or date of death, whichever came first, assessed up to 28 daysDescription: The target level of respiratory movements - 28 per minute or less with self-breathing, is used as one of the clinical improvement criteria
Measure: Respiratory movements rate (amount per minute), with self-breathing Time: From date post-onset of severe pneumonia to date of patient discharge or date of death, whichever came first, assessed up to 28 daysDescription: Measured in degrees Celsius. Fever absence (body temperature no more 37 degrees Celsius) during at least 24 hours without antipyretics, is used as one of the clinical improvement criteria.
Measure: Body temperature without antipyretics use Time: From date post-onset of severe pneumonia to date of patient discharge or date of death, whichever came first, assessed up to 28 daysDescription: The target level 1000 cells / mm3 and above is used as one of the clinical improvement criteria (applicable for patients with lymphocytes count lower 1000 cells / mm3 at screening moment)
Measure: Lymphocyte count Time: From date post-onset of severe pneumonia to date of patient discharge or date of death, whichever came first, assessed up to 28 daysDescription: Period duration (in days)
Measure: Time from the onset of the disease to discharge, in days Time: 28 daysDescription: Number of days with ventilatory support
Measure: Duration of the need for ventilatory support, in days Time: 28 daysDescription: Number of days in the intensive care unit
Measure: Duration of the need for intensive care, in days Time: 28 daysDescription: Number of days with necessery of oxygenation support
Measure: Duration of need for oxygenation in days (SPO2 ≤ 93% with self-breathing) Time: 28 daysDescription: Measuring the analyte concentration in plasma (mg/L)
Measure: The C-reactive protein (CRP) level Time: Day 0 (screening), day 5, day 14, day 28Description: Measuring the analyte concentration in plasma (pg/mL)
Measure: The tumor necrozis factor alpha (TNF-α) level Time: Day 0 (screening), day 5, day 14, day 28Description: Measuring the analyte concentration in plasma (pg/mL)
Measure: The interleukin-1β (IL-1β) level Time: Day 0 (screening), day 5, day 14, day 28Description: Measuring the analyte concentration in plasma (pg/mL)
Measure: The interleukin-6 (IL-6) level Time: Day 0 (screening), day 5, day 14, day 28Description: Measuring the analyte concentration in plasma (µg FEU/mL)
Measure: The D-dimer level Time: Day 0 (screening), day 5, day 14, day 28Description: Measuring the analyte concentration in plasma (g/L)
Measure: The Complement (C3 component) level Time: Day 0 (screening), day 5, day 14, day 28Description: Measuring the analyte concentration in plasma (U/mL)
Measure: The Circulating immune complexes level Time: Day 0 (screening), day 5, day 14, day 28Description: Analyte concentration in plasma (ng/mL)
Measure: The ferritin level Time: Day 0 (screening), day 5, day 14, day 28Description: Analyte concentration in plasma (ng/mL)
Measure: The procalcitonin level Time: Day 0 (screening), day 5, day 14, day 28Description: The IgG-subtypes (IgG1-IgG4) concentration in plasma (mg/dL)
Measure: IgG subtypes Time: Day 0 (screening), day 5, day 14, day 28Description: Survivealance estimation
Measure: Survival assessment for a 28-day follow-up period since the onset of severe pneumonia Time: 28 daysDescription: Number of participants with adverse reactions related by investigational drug as assessed by CTCАЕ v 4.0
Measure: Frequency of side effects Time: 28 daysDescription: Number of participants with serious adverse reactions related by investigational drug as assessed by CTCАЕ v 4.0
Measure: Frequency of serious side effects Time: 28 daysThe purpose of this Pilot Study is to establish a hypothesis of whether or not intravenous immunoglobulin (IVIG) may impact the hospital length of stay, if started within 48 of mechanical ventilation in patients infected with SARS-CoV-2 virus.
Description: Assess hospital length of stay after mechanical ventilation
Measure: Hospital length of stay Time: Up to 60 daysDescription: Analyze the blood to assess the human metabolome and proteome in patients with COVID-19 receiving IVIG including production of inflammatory and anti-inflammatory cytokines, markers of endothelial injury, and coagulation using Mass Spectrometry
Measure: Human metabolome and proteome Time: Up to 60 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports